Emergence and treatment of multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis in South Africa

Infection, Genetics and Evolution

Volumn 12, Issue 4, 2012, Pages 686-694

  Streicher, Elizabeth M ^a   Müller, Borna ^a   Chihota, Violet ^a,b   Mlambo, Charmaine ^c   Tait, Marisa ^a   Pillay, Manormoney ^d   Trollip, Andre ^a   Hoek, Kim G P ^a   Sirgel, Frederick A ^a   Gey van Pittius, Nicolaas C ^a   van Helden, Paul D ^a   Victor, Thomas C ^a   Warren, Robin M ^a  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b AURUM INSTITUTE   (South Africa)

^c International Center for AIDS Care and Treatment Programs (ICAP)   (Swaziland)

^d UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

Drug resistance; Evolution; MDR TB; Surveillance; XDR TB

Indexed keywords

TUBERCULOSTATIC AGENT;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GENE; BACTERIAL LOAD; BACTERIAL TRANSMISSION; BACTERIUM DETECTION; CONTROLLED STUDY; DELAYED DIAGNOSIS; DISEASE COURSE; DNA SEQUENCE; EPIDEMIC; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENE MUTATION; GEOGRAPHIC DISTRIBUTION; HUMAN; MOLECULAR EPIDEMIOLOGY; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; SOUTH AFRICA; TREATMENT FAILURE; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ANTITUBERCULAR AGENTS; DELAYED DIAGNOSIS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; GENOTYPE; HUMANS; MYCOBACTERIUM TUBERCULOSIS; PHYLOGEOGRAPHY; PRACTICE GUIDELINES AS TOPIC; SOUTH AFRICA; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84859924241     PISSN: 15671348     EISSN: 15677257     Source Type: Journal    
DOI: 10.1016/j.meegid.2011.07.019     Document Type: Article

References (47)

1. Abe C., Kobayashi I., Mitarai S., Wada M., Kawabe Y., Takashima T., Suzuki K., Sng L.H., Wang S., Htay H.H., Ogata H. Biological and molecular characteristics of Mycobacterium tuberculosis clinical isolates with low-level resistance to isoniazid in Japan. J. Clin. Microbiol. 2008, 46:2263-2268.
2. Barnard M., Albert H., Coetzee G., O'Brien R., Bosman M.E. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am. J. Respir. Crit Care Med. 2008, 177:787-792.
3. Baulard A.R., Betts J.C., Engohang-Ndong J., Quan S., McAdam R.A., Brennan P.J., Locht C., Besra G.S. Activation of the pro-drug ethionamide is regulated in mycobacteria. J. Biol. Chem. 2000, 275:28326-28331.
4. Calver A.D., Falmer A.A., Murray M., Strauss O.J., Streicher E.M., Hanekom M., Liversage T., Masibi M., van Helden P.D., Warren R.M., Victor T.C. Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa. Emerg. Infect. Dis. 2010, 16:264-271.
5. Cox H.S., McDermid C., Azevedo V., Muller O., Coetzee D., Simpson J., Barnard M., Coetzee G., van C.G., Goemaere E. Epidemic levels of drug resistant tuberculosis (MDR and XDR-TB) in a high HIV prevalence setting in Khayelitsha, South Africa. PLoS. One. 2010, 5:e13901.
6. Cox H.S., Sibilia K., Feuerriegel S., Kalon S., Polonsky J., Khamraev A.K., Rusch-Gerdes S., Mills C., Niemann S. Emergence of extensive drug resistance during treatment for multidrug-resistant tuberculosis. N. Engl. J. Med. 2008, 359:2398-2400.
7. Department of Health. 2000. The South African Tuberculosis Control Programme Practical Guidelines 2000. Available at: <> (accessed 30.05.11). http://www.capegateway.gov.
8. Department of Health Government South Africa. 2006. Report on TB, Including XDR-TB in South Africa. Available at: <> (accessed 21.7.11). http://www.doh.gov.za.
9. Department of Health Government South Africa. 2007. Tuberculosis strategic plan for South Africa 2007-2011. Available at: <> (accessed 30.05.11). http://www.info.gov.za.
10. Devasia R.A., Blackman A., May C., Eden S., Smith T., Hooper N., Maruri F., Stratton C., Shintani A., Sterling T.R. Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT 960, MODS and nitrate reductase assay and fluoroquinolone cross-resistance. J. Antimicrob. Chemother. 2009, 63:1173-1178.
11. Dheda K., Shean K., Zumla A., Badri M., Streicher E.M., Page-Shipp L., Willcox P., John M.A., Reubenson G., Govindasamy D., Wong M., Padanilam X., Dziwiecki A., van Helden P.D., Siwendu S., Jarand J., Menezes C.N., Burns A., Victor T., Warren R., Grobusch M.P., van der W.M., Kvasnovsky C. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet 2010, 375:1798-1807.
12. Gandhi N.R., Moll A., Sturm A.W., Pawinski R., Govender T., Lalloo U., Zeller K., Andrews J., Friedland G. Extensively Drug Resistant Tuberculosis as a cause of death in patients co-infected with Tuberculosis and HIV in a rural area of South Africa. Lancet 2006, 368:1575-1580.
13. Hanekom M., van der Spuy G.D., Streicher E., Ndabambi S.L., McEvoy C.R., Kidd M., Beyers N., Victor T.C., van Helden P.D., Warren R.M. A recently evolved sublineage of the Mycobacterium tuberculosis Beijing strain family is associated with an increased ability to spread and cause disease. J. Clin. Microbiol. 2007, 45:1483-1490.
14. Hoek, K.G.P., Schaaf, H.S., Gey van Pittius, N.C., Van Helden, P.D., and Warren, R.M. Resistance to pyrazinamide and ethambutol compromises MDR/XDR-TB treatment. 99th ed., 2009. pp. 785-787.
15. Jacobson K.R., Tierney D.B., Jeon C.Y., Mitnick C.D., Murray M.B. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin. Infect. Dis. 2010, 51:6-14.
16. Johnson R., Jordaan A.M., Pretorius L., Engelke E., Vander S.G., Kewley C., Bosman M., van Helden P.D., Warren R., Victor T.C. Ethambutol resistance testing by mutation detection. Int. J. Tuberc. Lung Dis. 2006, 10:68-73.
17. Johnson R., Warren R.M., Strauss O.J., Jordaan A., Falmer A.A., Beyers N., Schaaf H.S., Murray M., Cloete K., van Helden P.D., Victor T.C. An outbreak of drug resistant Tuberculosis caused by a Beijing strain in the Western Cape, South Africa. Int. J. Tuberc. Lung Dis. 2006, 10:1412-1414.
18. Johnson R., Warren R.M., van der Spuy G.D., Gey van Pittius N.C., Theron D., Streicher E.M., Bosman M., Coetzee G.J., van Helden P.D., Victor T.C. Drug-resistant tuberculosis epidemic in the Western Cape driven by a virulent Beijing genotype strain. Int. J. Tuberc. Lung Dis. 2010, 14:119-121.
19. Kam K.M., Yip C.W., Cheung T.L., Tang H.S., Leung O.C., Chan M.Y. Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis: correlation with ofloxacin susceptibility. Microb. Drug Resist. 2006, 12:7-11.
20. Kok, P., O'Donovan, M., Bouare, O., van Zyl, J. 2003. Post Apartheid Patterns of Internal Migration in South Africa. Available at: (accessed 20.07.11). http://www.hsrcpress.ac.za.
21. Kvasnovsky C.L., Cegielski J.P., Erasmus R., Siwisa N.O., Thomas K., der Walt M.L. Extensively drug-resistant TB in Eastern Cape, South Africa: high mortality in HIV-Negative and HIV-Positive Patients. J.Acquir.Immune.Defic.Syndr. 2011, 57:146-152.
22. Louw G.E., Warren R.M., Donald P.R., Murray M.B., Bosman M., van Helden P.D., Young D.B., Victor T.C. Frequency and implications of pyrazinamide resistance in managing previously treated tuberculosis patients. Int J. Tuberc. Lung Dis. 2006, 10:802-807.
23. Loveday M., Thomson L., Chopra M., Ndlela Z. A health systems assessment of the KwaZulu-Natal tuberculosis programme in the context of increasing drug resistance. Int. J. Tuberc. Lung Dis. 2008, 12:1042-1047.
24. Mlambo C.K., Warren R.M., Poswa X., Victor T.C., Duse A.G., Marais E. Genotypic diversity of extensively drug-resistant tuberculosis (XDR-TB) in South Africa. Int. J. Tuberc. Lung Dis. 2008, 12:99-104.
25. Morlock G.P., Metchock B., Sikes D., Crawford J.T., Cooksey R.C. EthA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob. Agents Chemother. 2003, 47:3799-3805.
26. Mphahlele M., Syre H., Valvatne H., Stavrum R., Mannsaker T., Muthivhi T., Weyer K., Fourie P.B., Grewal H.M. Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates. J. Clin. Microbiol. 2008, 46:3459-3464.
27. Müller B., Streicher E.M., Hoek K.G., Tait M., Trollip A., Bosman M.E., Coetzee G.J., Chabula-Nxiweni E.M., Hoosain E., Gey Van Pittius N.C., Victor T.C., van Helden P.D., Warren R.M. InhA promoter mutations: a gateway to extensively drug-resistant tuberculosis in South Africa?. Int. J. Tuberc. Lung Dis. 2011, 15:344-351.
28. National Health Laboratory Services, 2010. National Institute for Communicable Diseases - Annual Report 2009. Available at: http://www.nicd.ac.za.
29. Pillay M., Sturm A.W. Evolution of the extensively drug-resistant F15/LAM4/KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. Clin. Infect. Dis. 2007, 45:1409-1414.
30. Shean K.P., Willcox P.A., Siwendu S.N., Laserson K.F., Gross L., Kammerer S., Wells C.D., Holtz T.H. Treatment outcome and follow-up of multidrug-resistant tuberculosis patients, West Coast/Winelands, South Africa, 1992-2002. Int. J. Tuberc. Lung Dis. 2008, 12:1182-1189.
31. Sirgel, F.A., Tait, M., Warren, R.M., Streicher, E.M., Bottger, E.C., Van Helden, P.D., Gey Van Pittius, N.C., Coetzee, G., Hoosain, E.Y., Chabula-Nxiweni, M., Hayes, C., Victor, T.C., Trollip, A., 2011. Mutations in the rrs A1401G gene and phenotypic resistance to amikacin and capreomycin in Mycobacterium tuberculosis. Microb.Drug Resist.
32. Strauss O.J., Warren R.M., Jordaan A., Streicher E.M., Hanekom M., Falmer A.A., Albert H., Trollip A., Hoosain E., van Helden P.D., Victor T.C. Spread of a low-fitness drug-resistant Mycobacterium tuberculosis strain in a setting of high human immunodeficiency virus prevalence. J. Clin. Microbiol. 2008, 46:1514-1516.
33. Streicher E.M., Warren R.M., Kewley C., Simpson J., Rastogi N., Sola C., van der Spuy G.D., van Helden P.D., Victor T.C. Genotypic and phenotypic characterization of drug-resistant Mycobacterium tuberculosis isolates from rural districts of the Western Cape Province of South Africa. J. Clin. Microbiol. 2004, 42:891-894.
34. van Rie A., Warren R.M., Beyers N., Gie R.P., Classen C.N., Richardson M., Sampson S.L., Victor T.C., van Helden P.D. Transmission of a multidrug-resistant Mycobacterium tuberculosis strain resembling " strain W" among noninstitutionalized, human immunodeficiency virus-seronegative patients. J. Infect. Dis. 1999, 180:1608-1615.
35. Van Rie A., Enarson D. XDR tuberculosis: an indicator of public-health negligence. Lancet 2006, 368:1554-1556.
36. Via L.E., Cho S.N., Hwang S., Bang H., Park S.K., Kang H.S., Jeon D., Min S.Y., Oh T., Kim Y., Kim Y.M., Rajan V., Wong S.Y., Shamputa I.C., Carroll M., Goldfeder L., Lee S.A., Holland S.M., Eum S., Lee H., Barry C.E. Polymorphisms associated with resistance and cross-resistance to aminoglycosides and capreomycin in Mycobacterium tuberculosis isolates from South Korean Patients with drug-resistant tuberculosis. J. Clin. Microbiol. 2010, 48:402-411.
37. Victor T.C., Streicher E.M., Kewley C., Jordaan A.M., van der Spuy G.D., Bosman M., Louw H., Murray M., Young D., van Helden P.D., Warren R.M. Spread of an emerging Mycobacterium tuberculosis drug-resistant strain in the Western Cape of South Africa. Int. J. Tuberc. Lung Dis. 2007, 11:195-201.
38. Weyer K. 2001. Survey of Tuberculosis drug resistance, 2001-2002, Western Cape. Available at: <> (accessed 2.06.2011). http://www.sahealthinfo.org.
39. Weyer K., Groenewald P., Zwarenstein M., Lombard C.J. Tuberculosis drug resistance in the Western Cape. S. Afr. Med. J. 1995, 85:499-504.
40. Weyer K., Kleeberg H.H. Primary and acquired drug resistance in adult black patients with tuberculosis in South Africa: results of a continuous national drug resistance surveillance programme involvement. Tuber. Lung Dis. 1992, 73:106-112.
41. WHO. 2010a. Multidrug and extensively drug-resistant TB (M/XDR-TB) 2010 Global report on surveillance and response. Available at: <> (accessed 26.06.10a). http://whqlibdoc.who.int.
42. WHO, 2010b. WHO endorses new rapid tuberculosis test. Available at: <> (accessed 8.12.10b). http://www.who.int.
43. WHO media report, 2006. WHO Global Task Force outlines measures to combat XDR-TB worldwide. Available at: <> (accessed 1.11.06). http://www.who.int.
44. WHO media report, New rapid tests for drug-resistant TB for developing countries, and New rapid tests for drug-resistant TB for developing countries. 2008. New rapid tests for drug-resistant TB for developing countries. Available at: <> (accessed 9.9.08). http://www.who.int.
45. WHO-IUATLD Global Project on anti-tuberculosis drug resistance surveillance. 2008. Ant-tuberculosis drug resistance in the world (Report No 4). Available at: <> (accessed 30.4.08). http://www.who.int.
46. World Health Oganization, 2009. Global Tuberculosis Control 2009. Available at: <> (accessed 8.2.10). http://whqlibdoc.who.int.
47. World Health Organization, 2008. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. Available at: <> (accessed 8.9.2009). http://whqlibdoc.who.int.